Immune-modulating peptide

A pharmaceutical composition comprising a peptide of which its amino acid sequence is selected from the group consisting of SEQ ID NO:

• 1 to SEQ ID NO:
• 24;
• or a substance derived from the peptide of which its amino acid sequence is selected from the group consisting of SEQ ID NO:
• 1 to SEQ ID NO:
• 24.

A method of treating a condition accompanied or caused by modification of the number or activation states of leukocytes comprising administering to a host in need of such treatment a therapeutically effective amount of peptides having an amino acid sequence selected from the group consisting of SEQ ID NO:

• 1 to SEQ ID NO:
• 24 or a substance derived from the peptide of which the amino acid sequence is selected from the group consisting of SEQ ID NO:
• 1 to SEQ ID NO:
• 24.

A method of increasing the number or raising the activation state of leukocytes in a host comprising administering to a host in need of a greater number or higher activation state of leukocytes a therapeutically effective amount of peptides having an amino acid sequence selected from the group consisting of SEQ ID NO:

• 1 to SEQ ID NO:
• 24 or a substance derived from the peptide of which the amino acid sequence is selected from the group consisting of SEQ ID NO:
• 1 to SEQ ID NO:
• 24.

A method of inducing extracellular calcium increase in leukocytes in a patient in need of such treatment, the method comprising administering to said patient an amount of a peptide having an amino acid sequence from the group consisting of SEQ ID NO:

• 1 to SEQ ID NO:
• 24 or a substance derived from the peptide of which the amino acid sequence is selected from the group consisting of SEQ ID NO:
• 1 to SEQ ID NO:
• 24 in an amount effective to therapeutically or prophylactically achieve such induction or desensitization.

A method of inducing superoxide generation by human monocytes or neutrophils in a patient in need of such treatment, the method comprising administering to said patient an amount of a peptide having an amino acid sequence selected from the group consisting of SEQ ID NO:

• 1 to SEQ ID NO:
• 24 or a substance derived from the peptide of which the amino acid sequence is selected from the group consisting of SEQ ID NO:
• 1 to SEQ ID NO:
• 24 in an amount effective to therapeutically or prophylactically achieve such induction or desensitization.

A method of inducing chemotactic migration by human peripheral blood mononuclear cells in a patient in need of such treatment, the method comprising administering to said patient an amount of a peptide having an amino acid sequence selected from the group consisting of SEQ ID NO:

• 1 to SEQ ID NO:
• 24 or a substance derived from the peptide of which the amino acid sequence is selected from the group consisting of SEQ ID NO:
• 1 to SEQ ID NO:
• 24 in an amount effective to therapeutically or prophylactically achieve such induction or desensitization.

A method of inducing degranulation in formyl peptide receptor or formyl peptide receptor-like 1 expressing cells in a patient in need of such treatment, the method comprising administering to said patient an amount of a peptide having an amino acid sequence selected from the group consisting of SEQ ID NO:

• 1 to SEQ ID NO:
• 24 or a substance derived from the peptide of which the amino acid sequence is selected from the group consisting of SEQ ID NO:
• 1 to SEQ ID NO:
• 24 in an amount effective to therapeutically or prophylactically achieve such induction or desensitization.

A method of competing peptides with WKYMVm for binding formyl peptide receptor in the formyl peptide receptor expressing cells, in a patient in need of such treatment, the method comprising administering to said patient an amount of a peptide having an amino acid sequence selected from the group consisting of SEQ ID NO:

• 1 to SEQ ID NO:
• 24 or a substance derived from the peptide of which the amino acid sequence is selected from the group consisting of SEQ ID NO:
• 1 to SEQ ID NO:
• 24 in an amount effective to therapeutically or prophylactically achieve such induction or desensitization.

A method of competing peptides with WKYMVm for binding a formyl peptide receptor-like 1 in the formyl peptide receptor-like 1 expressing cells, in a patient in need of such treatment, the method comprising administering to said patient an amount of a peptide having an amino acid sequence selected from the group consisting of SEQ ID NO:

• 1 to SEQ ID NO:
• 24 or a substance derived from the peptide of which the amino acid sequence is selected from the group consisting of SEQ ID NO:
• 1 to SEQ ID NO:
• 24 in an amount effective to therapeutically or prophylactically achieve such induction or desensitization.

A method of stimulating extracellular signal regulated protein kinase in formyl peptide receptor or formyl peptide receptor-like 1 expressing cells in a patient in need of such treatment, the method comprising administering to said patient an amount of a peptide having an amino acid sequence selected from the group consisting of SEQ ID NO:

• 1 to SEQ ID NO:
• 24 or a substance derived from the peptide of which the amino acid sequence is selected from the group consisting of SEQ ID NO:
• 1 to SEQ ID NO:
• 24 in an amount effective to therapeutically or prophylactically achieve such induction or desensitization.

A method of stimulating Akt in formyl peptide receptor or formyl peptide receptor-like 1 expressing cells in a patient in need of such treatment, the method comprising administering to said patient an amount of a peptide having an amino acid sequence selected from the group consisting of SEQ ID NO:

• 1 to SEQ ID NO:
• 24 or a substance derived from the peptide of which the amino acid sequence is selected from the group consisting of SEQ ID NO:
• 1 to SEQ ID NO:
• 24 in an amount effective to therapeutically or prophylactically achieve such induction or desensitization.